Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: The example of oral disintegrating tablet of olanzapine;Formulazioni farmaceutiche e aderenza al trattamento farmacologico in psichiatria: L'esempio della formulazione orodispersibile di olanzapina

Rivista di Psichiatria

Volumn 47, Issue 1, 2012, Pages 30-39

  Cecchi, Cristiana ^a   Canonico, Pier Luigi ^b  

^a ASL 10   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Adherence; Bipolar disorder; Compliance; Olanzapine; Oral disintegrating tablets; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HEALTH ECONOMICS; HUMAN; MENTAL PATIENT; ORALLY DISINTEGRATING TABLET; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHIATRY; REVIEW;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICATION ADHERENCE; PHARMACEUTICAL PREPARATIONS; TABLETS;

EID: 84857711698     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: 10.1708/1034.11289     Document Type: Review

References (53)

1. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000; (407): 83-6. (Pubitemid 32115754)
2. Colom F, Argyropoilos S, Vieta E. Non-adherence in bipolar disorders: more than a wrong decision. In: Veta E (ed). Bipolar disorders: clinical and therapeutic progress. Madrid: Panamericana, 2001; pp. 169-83.
3. Hogarty GE, Goldberg SC, Schooler NR, et al. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 1974; 31: 603-8.
4. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-29.
5. Frank E, Perel JM, Mallinger AG, et al. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull 1992; 28: 231-5.
6. Haynes RB, Sackett DL. Compliance in health care. Baltimore, MD: Johns Hopkins Press. 1979
7. National Institute of Health. Research on adherence to interventions for mental disorders. Available at http: //www.grants.nih.gov/grants/guide/pa-files/ PA-03-111.html.
8. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc 2000; 40: 475-85.
9. Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year followup of first-admitted subjects. Acta Psychiatr Scand 2000; 102: 203-10. (Pubitemid 30663329)
10. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64 (suppl 16): 10-3. (Pubitemid 37523322)
11. Colom F, Vieta E, Martínez A, et al. What is the role of psychotherapy in the treatment of bipolar disorders? Psychother Psychosom 1998; 67: 3-9. (Pubitemid 28039447)
12. Reinares M, Colom F, Martínez-Arán A, et al. Therapeutic interventions focused on the family of bipolar patients. Psychother Psychosom 2002; 71: 2-10.
13. Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry 2000; 177: 440-6.
14. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000; 101: 119-24. (Pubitemid 30084422)
15. Colom F, Vieta E. Non-adherence in psychiatric disorders: misbehaviour or clinical feature? Acta Psychiatr Scand 2002: 105: 161-3. (Pubitemid 34280687)
16. San L, Casillas M, Ciudad A, et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther 2008; 14: 203-14.
17. US Food and Drug Administration [online] - Guidance for Industry - Orally Disintegrating Tablets - Available from URL: www.fda.gov/downloads/Drugs/.../ Guidances/ucm070578.pdf
18. Brown D. Orally disintegrating tablets. Taste over speed. Drug delivery technology. Vol. 3 No. 6 September 2003, Posted On: 3/28/2008
19. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50: 375-82. (Pubitemid 28197414)
20. De Roche CC. Consumer preference for orally disintegrating tablets over conventional forms of medication: evolving methodology for medication intake in dysphagia. Abstracts of Posters Presented at the Twelfth Annual Meeting of the Dysphagia Research Society, San Francisco, California, USA, October 2-4, 2003. Disphagia 2005; 20: 77-86.
21. Shen YC, Lee MY, Lin CC, et al. Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharyngitis. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 541-2. (Pubitemid 46209408)
22. Tornatore FL. Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia. J Clin Psychiatry 2005; 66: 1493-4 [Author reply to: J Clin Psychiatry 2005; 66: 122-33].
23. Thyssen A, Remmerie B, D'Hoore P, et al. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther 2007; 29: 290-304. (Pubitemid 46661862)
24. Bergstrom RF, Mitchell M, Witcher J, et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophr Res 2004; 67 (suppl 1): 160.
25. Witcher JW, Bergstrom RF, Cerimele BJ, et al. Pharmacokinetics and bioequivalence of olanzapine rapidly-disintegrating tablets. [abstract no.3431]. American Association of Pharmacists Annual Meeting; 1998 Nov 15-19; San Francisco (CA). Available at URL: http://www.aapsj.org/abstracts/AM-1998/3431. html
26. Zyprexa-EPAR Summary for the public. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR---Summary- for-the-public/human/000115/ WC500055202.pdf
27. Zyprexa Zydis (Olanzapine ODT). Approved Agreed-Upon Labeling. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2004/20592se1- 019-zyprexa-lbl.pdf
28. Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006; 46: 164-71. (Pubitemid 43146447)
29. Chue P, Jones B, Taylor CC, Dickson R. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry 2002; 47: 771-4. (Pubitemid 35345722)
30. Hobbs D, Karaganis J, Treuer T, et al. An in vitro analysis of disintegration times of different formulations of orally disintegrating. 10th World Congress of Biological Psychiatry; Prague, Czech Republic; May 29-June 02, 2011.
31. data on file: Eli Lilly and Company.
32. Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill, non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003; 6: 97-102. (Pubitemid 36850960)
33. Dardennes R, Chartier F, Heurtebize N, et al. Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: an observational prospective study. Int J Neuropsychopharmacol 2004; 7 (suppl 2): P01.389.
34. Czekalla J, Wagner T, Schacht A, et al. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 2007; 1: 19-27.
35. Hori H, Ueda N, Yoshimura R, et al. Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry 2009; 10: 741-5.
36. Rouillon, F, Chartier F, Lukasiewicz M, et al. Effectiveness of olanzapine standard oral tablet and orally disintegrating tablet in a 1-year European observational study. 23rd European College of Neuropsychopharmacology Congress (ECNP); Amsterdam, The Netherlands; 28 August-1 September 2010.
37. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76. (Pubitemid 18039085)
38. Guy W. Clinical Global Impressions ECDEU Assessment. Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76-338). Rockville, MD: National Institute of Mental Health, 1976; 218-22.
39. Pascual JC, Perez V, Martin JL, et al. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas Esp Psiquiatr 2007; 35: 47-51.
40. Hatta K, Kawabata T, Yoshida K, et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry 2008; 30: 367-71. (Pubitemid 351862316)
41. Wen-Yu Hsu, Si-Sheng Huang, Bo-Shyan Lee, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30: 230-4.
42. de Haan L, van Amelsvoort T, Rosien K, et al. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl) 2004; 175: 389-90. (Pubitemid 39361928)
43. Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol 2008; 23: 211-6. (Pubitemid 351577690)
44. Stip E, Anselmo K, Wolfe M, et al. Long-term treatment with atypical antipsychotics and risk of weight gain. Drug Saf 2006; 29: 550-2 [Author reply 552 to: Drug Saf 2006; 29: 303-19].
45. Arranz B, San L, Dueñas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol 2007; 22: 11-5. (Pubitemid 46178773)
46. Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophrenia Research 2009; 113: 41-8.
47. Eberle-Wang K, Braun BT, Simansky KJ. Serotonin contracts the isolated rat pylorus via a 5-HT2-like receptor. Am J Physiol 1994; 266: R284-R291.
48. Crocq MA, Guillon MS, Bailey PE, et al. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry 2007; 22: 453-4. (Pubitemid 47600624)
49. Karagianis J, Landry J, Milev R, et al. A 16-week, randomized, doublet blind, double dummy trial of sublingual orally disintegrating olanzapine vs standard olanzapine tablets in patients who gained weight during olanzapine treatment: the PLATYPUS Study. Schizophr Res 2008; 102/1-3 (suppl 2): 238.
50. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 20: 297-310. (Pubitemid 24171093)
51. Weiden PJ, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In: Shriqui C, Nasrallah H (eds). Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press, 1995; 463-85.
52. Perry PJ, Sanger T, Beasly C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472-7. (Pubitemid 28389187)
53. Bitter I, Treuer T, Dilbaz N, et al. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry 2010; 11: 894-903.